There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results